TriSalus Life Sciences Stock

trisaluslifesci.comHealthcare / BioTech & PharmaFounded: 2009Funding to Date: $198.81MM

TriSalus Life Sciences is a biopharma company that specializes in treatment research and development for tumors of the liver and pancreas. TriSalus involves a team of clinicians and scientists who develop systemic immunotherapies to fight tumors through its developed drug delivery methods.

Register To Buy and Sell Shares

For more details on financing and valuation for TriSalus Life Sciences, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access TriSalus Life Sciences’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like TriSalus Life Sciences.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.


Management Team

Mary Szela
Chief Executive Officer and President
Steven C. Katz, MD, FACS
Chief Medical Officer, Scientific Advisory Board Chairman
Sean Murphy
Chief Financial Officer
Trevor McCaw
Chief Commercial Officer
Bryan F. Cox, PhD
Chief of Research
Jennifer L. Stevens, JD
Chief Regulatory Officer
Richard B. Marshak VMD, MBA
Business Development & Strategy, SVP

Board Members

Beverly Huss
Sean Murphy
Malin Corporation
John Tullis
Tullis Health Partners
Norman Weldon
Partison Management Group
Karen Cassidy
Partisan Management Group
Mark T. Lupa
High Country Venture
Ginger Graham
Independent Director
Mats Wahlstrom
KMG Capital Partners

News Highlights

TriSalus merges with MedTech Acquisition to bolster cash reserves
TriSalus Life Sciences has merged with MedTech Acquisition Corporation to increase their cash reserves and fund developmental and commercial milestones. The merged company will trade on Nasdaq under the symbols "TLSI" and "TLSIW". The merger is expected to provide a cash runway until mid-2024 to support various plans, including the development of a cancer therapy.
Updated on: May 21, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.